<DOC>
	<DOCNO>NCT01398462</DOCNO>
	<brief_summary>CWP232291 block proliferation cancer cell via activation caspase . Active caspase show target beta-catenin , hallmark canonical Wnt signaling , degradation caspase-directed cleavage . CWP232291 target beta-catenin degradation thereby inhibit expression cell cycle anti-apoptotic gene cyclin D1 survivin .</brief_summary>
	<brief_title>Phase I Clinical Study CWP232291 Acute Myeloid Leukemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<criteria>Able understand willing sign inform consent form ( ICF ) prior initiation studyspecific procedure treatment 18 year age 3 . A pathologically confirm diagnosis AML CMML2 World Health Organization ( WHO ) classification relapse refractory current therapy anticipate result durable remission , MDS WHO classification RAEB1 RAEB2 fail least three cycle hypomethylating therapy , primary ( PMF ) , postpolycythemia vera ( PPMF ) postessential thrombocythemia ( PTMF ) MF WHO classification , highrisk category Dynamic International Prognostic Scoring System ( DIPSS Plus ) , ≥1 % circulate blast , fail treatment ruxolitinib Eastern Cooperative Oncology Group ( ECOG ) performance score 02 In absence rapidly progress disease , interval prior treatment time study drug administration least 2 week cytotoxic agent least 5 halflives noncytotoxic agent . If patient hydroxyurea control peripheral blood leukemic cell count , patient must discontinue hydroxyurea least 24 hour initiation treatment study drug . Persistent clinically significant toxicity prior chemotherapy must great grade 1 Adequate renal function : Serum creatinine =/ &lt; 2.0mg/dL Adequate hepatic function : Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) , unless consider due Gilbert 's syndrome Alkaline phosphatase ( AP ) =/ &lt; 2.5 x ULN Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤3 x ULN , unless consider due organ leukemic involvement Women childbearing potential ( i.e. , woman pre menopausal surgically sterile ) must use acceptable contraceptive method ( abstinence , intrauterine device [ IUD ] , oral contraceptive , double barrier device ) , must negative serum urine pregnancy test within 2 week prior begin treatment trial . Sexually active men must also use acceptable contraceptive method duration time study Able adhere study visit schedule protocol requirement Uncontrolled intercurrent illness include , limited , uncontrolled infection , symptomatic congestive heart failure ( CHF ) , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Active heart disease include myocardial infarction ( MI ) within previous 3 month , symptomatic coronary artery disease ( CAD ) , arrhythmias control medication , uncontrolled CHF Active central nervous system ( CNS ) disease Therapy standard investigational treatment hematologic malignancy ( except hydroxyurea , mention inclusion criterion ) Therapy anticoagulant antithrombotic agent ( include aspirin ) within 7 day prior study drug administration History gastrointestinal ( GI ) hemorrhage Known positive status human immunodeficiency virus ( HIV ) and/or active hepatitis B C Pregnant nursing woman . Pregnant nursing patient exclude effect CWP232291 fetus nursing child unknown . Patients eligible bone marrow transplant , regardless age Patients FLT3 ITD positive AML AML patient cytogenetic abnormality eligible trial target investigational agent investigator feel great benefit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>